The National Guard Health Affairs guidelines for the medical management of renal transplant patients

Ziad Arabi; Abdulrahman Theaby; Mahfooz Farooqui; Mubarak Abdalla; Ali Hajeer; Khalid Abdullah

doi:10.4103/1319-2442.248311

Instructions

Users online: 889


SPECIAL ARTICLE

Year : 2018 | Volume : 29 | Issue : 6 | Page : 1452-1469

The National Guard Health Affairs guidelines for the medical management of renal transplant patients

Ziad Arabi¹, Abdulrahman Theaby¹, Mahfooz Farooqui², Mubarak Abdalla², Ali Hajeer³, Khalid Abdullah⁴
¹ Consultant in Renal Transplantation, Adult Transplant Nephrology, Organ Transplant Center, King Abdulaziz Medical City, Riyadh, Saudi Arabia
² Consultant in Nephrology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
³ Professor of Laboratory Medicine and Immunology, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
⁴ Chairman, Organ Transplant Center and Hepatobiliary Sciences Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Click here for correspondence address and email

Date of Submission	09-Dec-2017
Date of Acceptance	09-Dec-2017
Date of Web Publication	27-Dec-2018

How to cite this article:
Arabi Z, Theaby A, Farooqui M, Abdalla M, Hajeer A, Abdullah K. The National Guard Health Affairs guidelines for the medical management of renal transplant patients. Saudi J Kidney Dis Transpl 2018;29:1452-69

How to cite this URL:
Arabi Z, Theaby A, Farooqui M, Abdalla M, Hajeer A, Abdullah K. The National Guard Health Affairs guidelines for the medical management of renal transplant patients. Saudi J Kidney Dis Transpl [serial online] 2018 [cited 2021 Jul 28];29:1452-69. Available from: https://www.sjkdt.org/text.asp?2018/29/6/1452/248311

Introduction

There are only few published international guidelines for renal transplant immunosuppression. International guidelines are generally specific to their population and there are no published guidelines in this area in Saudi Arabia. Here, we present the first guidelines for the medical management of renal transplant patients in KSA.

These guidelines were subject to an extensive review according to the most up-to-date international guidelines tighter with experience and literature in Saudi transplant patients.

These guidelines establish the standards for the management of kidney transplants including immunosuppression, infection prophylaxis, surveillance testing, treatment of rejection, ABO incompatible transplantation and desensitization.

The desensitization protocols detailed here for transplantation across incompatible HLA and ABO are presented in a very clear and stepwise approach for desensitization according to the estimated risk.

These guidelines also address several complex and commonly encountered issues such as the management of recipient with gallbladder disease, catheter-induced thrombosis, or supra vena cava obstruction. Antibiotic prophylaxis before dental procedures, intravenous fluid management post renal transplant and the timing of urinary stent removal are also reviewed.

These practical guidelines are designed to be easy to be read, follow, and adopt in the transplant centers.

These guidelines, like any other international guidelines, are based mostly on expert opinion and centers practices and not necessarily supported by well-established evidence from randomized controlled studies.

While these guidelines present personal recommendations from the authors and not endorsed by any formal society or institution, these guidelines present the first step to unify the practices among the transplant centers in KSA. This step is very essential for any future research to evaluate current practices in KSA.

In summary, these guidelines are one of the few internationally published guidelines of renal transplant immunosuppression with specific emphasis for transplant patients managed in KSA.

Table of Contents

List of abbreviations.........1453

Renal transplant immunosuppression.........1454

Kidney transplant prophylaxis.........1455

Surveillance testing.........1455

At-risk recipients for HBV.........1456

At-risk recipient for TB.........1456

At-risk for Schistosoma.........1456

At-risk for recurrent aHUS.........1457

Treatment of BK viremia.........1458

Treatment of CMV disease.........1458

Vaccinations.........1459

Treatment of acute rejection.........1459

Cellular mediated rejection (ACR).........1459

Antibody-mediated rejection (AMR).........1459

Alternative medications.........1460

Intravenous immune globulin administration guideline.........1461

Rituximab administration guideline.........1461

Bortezomib subcutaneous administration guideline.........1462

HLA incompatible kidney transplants.........1462

Risk stratification and desensitization protocol.........1462

Desensitization.........1463

DSA monitoring.........1463

Desensitization while on the waiting list of DDKT.........1463

ABO incompatible kidney transplant.........1463

Risk stratification of ABO-incompatible renal transplant.........1463

Desensitization protocol of ABO incompatible renal transplant.........1464

Urinary stent removal.........1466

PD catheter removal.........1466

Gallbladder disease.........1466

Catheter-induced thrombosis.........1466

SVC obstruction (symptomatic or asymptomatic).........1466

Antibiotic prophylaxis before dental procedures.........1466

IVF management post renal transplant.........1466

Acknowledgment.........1467

References.........1467

List of Abbreviations

AMR: Antibody-mediated rejection

CMV: Cytomegalovirus

CNI: Calcineurin inhibitors

DDKT: Deceased donor kidney transplant

DGF: Delayed graft function

DSA: Donor-specific antibodies

EBV: Epstein–Barr virus

FFP: Fresh frozen plasma

IVIG: Intravenous immunoglobulin

LATB: Latent tuberculosis infection

LKT: Living donor kidney transplant

MMF: Mycophenolate mofetil

PCN: Penicillin

PCR: Polymerase chain reaction

TB: Tuberculosis infection

BKV: BK virus

ACMR: Acute cell-mediated rejection

MFI: Mean fluorescence intensity

D: Donor

FK: Tacrolimus

PRA: Panel reactive antibody

ACR: Acute cellular rejection

PP: Plasmapheresis

R: Recipient

[Figure 1]

Figure 1: Management of refractory antibody-mediated rejection.
References: 1,3,25,26

Click here to view

[Table 1]

Table 1: Recipient antibody titer testing table.

Click here to view

[Table 2]

Table 2: Recipient antibody titer and number of required sessions of plasmapheresis.

Click here to view

[Table 3]

Table 3: Compatible recipient and donor fresh frozen plasma.

Click here to view

[Figure 2]

Figure 2: ABO desensitization protocol: Example: Initial Anti A/B IgG isoagglutinin titer 1:32.
References: 1,4,31,36,37,43-45

Click here to view

Many thanks to Almarastani, Mohamad; Al Tamimi, Abdulrahman; Kashkoush, Samy, Ohali, Wael Abdulazi; Faisal, Nabiha; Sibai, Abdul Razak; Al Khairy, Omar; Hajeer, Ali; Aloudah, Noura, Al Marshdi Al Otaibi, Nouf; Moaquel, Mohammed.

Conflict of interest: None declared.

This document was designed to aid the qualified health-care team in making clinical decisions about patient care, but it should not be construed as dictating exclusive courses of treatment and/or procedures. No health-care team member should view these documents and their bibliographic references as a final authority on patient care. Variations from these guidelines may be warranted in actual practice based on individual patient characteristics and clinical judgment in unique care circumstances.

References

1.	The Current Immunosuppression Practice at KAMC.
2.	Canadian Guidelines for Immunosuppression in Renal Transplant; 2017. http://www.transplant.bc.ca/Documents/Health%20Profess ionals/Clinical%20guidelines/Clinical%20Guidelines%20for%20Transplant%20Medications.pdf. [Last accessed on November 5, 2018].
3.	KDIGO Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009;9 (Suppl 3) :S1-155.
4.	Hardinger K, Brennan DC. Maintenance immunosuppressive therapy in kidney transplantation in adults. https://www.uptodate.com/contents/maintenance-immunosuppressive-therapy-in-kidney-transplantation-in-adults. [Last accessed on October 11 2018].
5.	Tropey N, Moghal N, Watson E, Talbot D. Handbook of Renal Transplantation. Oxford University Press: New York; 2010.
6.	Thymoglobulin® (Anti-Thymocyte Globulin [Rabbit]) Product Monograph. Quebec: Sanofi-Aventis Canada Inc.; 2016. http://products.sanofi.ca/en/thymoglobulin.pdf. [Last accessed on November 5, 2018].
7.	Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96:333-60.
8.	The Prevention and Management of CMV Disease after Solid Organ Transplantation. British Transplantation Society Guidelines. https://bts.org.uk/wp-content/uploads/2016/09/14_BTS_CMV_3RDE-1.pdf. [Last accessed on November 5, 2018].
9.	Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalo-virus in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:93-106.
10.	Azevedo LS, Pierrotti LC, Abdala E, et al. Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo) 2015;70(7):515-23.
11.	Carlos AQ Santos, John Vella, Daniel C Brennan. Clinical manifestations, diagnosis, and management of cytomegalovirus disease in kidney transplant recipients. https://www.Uptodate.com/contents/clinical-manifestations-diagnosis-and-management-of-cytomegalovirus-disease-in-kidney-transplant-recipients. [Last accessed November 2, 2018].
12.	Goto N, Futamura K, Okada M, et al. Management of Pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak. Clin Med Insights Circ Respir Pulm Med 2015;9:81-90.
13.	Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis pneumonia in solid-organ transplant recipients. J Fungi (Basel) 2015;1:293-331.
14.	Albumin: Creatinine Ratio (ACR) and Protein: Creatinine Ratio (PCR). Available from: http://www.gloshospitals.nhs.uk/en/WardsDepartments/Departments/Pathology/Pathology-Samples-and-Tests/Search/Chemical-Pathology/ProteinCreatinine-Ratio-PCR-urine/. [Last accessed on November 5, 2018].
15.	Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management. Am J Transplant 2015;15:1162-72.
16.	Subramanian A. Tuberculosis in solid organ transplant candidates and recipients. https://www.uptodate.com/contents/tuberculosis-in-solid-organ-transplant-candidates-and-recipients. [Last accessed November 1, 2018].
17.	Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyo-mavirus in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:179-88.
18.	Soliris® (Eculizumab). FDA. Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf. [Last accessed on November 5, 2018].
19.	Eculizumab. Dosage Forms & Strengths. Medscape; 27 May, 2017. Available from: http://www.reference.medscape.com/drug/soliris-eculizumab-342875. [Last accessed on November 5, 2018].
20.	Eculizumab (soliris®) Procedure for use in Patients Age ≤18 Years. http://www.ugotabug.med.miami.edu/documents/JMH-EculizumabProcedure.pdf. [Last accessed on November 5, 2018].
21.	Danziger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:311-7.
22.	Guidelines for vaccination in kidney transplant recipients. Indian J Nephrol 2016;26 Suppl 1: S19.
23.	Brennan DC, Malone A. Treatment of acute T cell-mediated (cellular) rejection of the renal allograft. https://www.uptodate.com/contents/treatment-of-acute-t-cell-mediated-cellular-rejection-of-the-renal-allograft [Last accessed on November 5, 2018].
24.	Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: A review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy 2014;34:733-44.
25.	Diamali A, Brennan DC. Prevention and treatment of antibody-mediated rejection of the renal allograft. UpToDate 2018. https://www.uptodate.com/contents/prevention-and-treatment-of-antibody-mediated-rejection-of-the-renal-allograft?search=25.%09Diamali% 20A,%20Brennan%20DC.%20Prevention%20 and%20treatment%20of%20antibody-mediated%20rejection%20of%20the%20renal %20allograft.&source=search_result&selected Title=1~150&usage_type=default&display_ra nk=1 [Last accessed on November 5, 2018].
26.	Ballow M, Shehata N. Overview of intravenous immune globulin (IVIG) therapy. https://www.uptodate.com/contents/overview-of-intravenous-immune-globulin-ivig-therapy. [Last accessed on November 5, 2018].
27.	Kurtin S, Knop CS, Milliron T. Subcutaneous administration of bortezomib: Strategies to reduce injection site reactions. J Adv Pract Oncol 2012;3:406-10.
28.	Living Donor Kidney Transplant Desensitization Protocol. Available from: http://www.Organdonationalliance.org/wp-content/uploads/toolbox.v.2/LivingdonorDesensensitizationProtocol3.2iTRIT.pdf. [Last accessed on November 5, 2018].
29.	Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013;13:76-85.
30.	Klein CL, Brennan DC. ABO incompatibility in kidney transplantation. https://www.uptodate.com/contents/abo-incompatibility-in-kidney-transplantation. [Last accessed on November 2, 2018].
31.	Klein CL, Brennan DC. HLA and ABO Sensitization and Desensitization in Renal Transplantation. https://www.uptodate.com/contents/abo-incompatibility-in-kidney-transplantation. [Last accessed on November 5, 2018].
32.	Keith DS, Vranic GM. Approach to the highly sensitized kidney transplant candidate. Clin J Am Soc Nephrol 2016;11:684-93.
33.	Marfo K, Lu A, Ling M, Akalin E. Desensiti-zation protocols and their outcome. Clin J Am Soc Nephrol 2011;6:922-36.
34.	Available from: http://www.organdonationalliance.org/wpcontent/uploads/toolbox.v.2/LivingdonorDesensensitizationProtocol3.2iTR IT.p. [Last accessed on November 5, 2018].
35.	Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 2015;15:2421-30.
36.	Schwenger V, Morath C. Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant 2010;25:2407-13.
37.	Honoré PM, Jacobs R, De Waele E, Van Gorp V, Spapen HD. Immunoadsorption versus therapeutic plasma exchange. Will fibrinogen make the difference? Blood Purif 2014;38:158-9.
38.	Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensiti-zation using IVIG and rituximab. Transplantation 2013;95:852-8.
39.	Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010;89:1095-102.
40.	Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immuno-globulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012;94:165-71.
41.	Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immuno-globulin and rituximab in highly sensitized patients. Transplantation 2012;94:345-51.
42.	Kozlowski T, Andreoni K. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant 2011 ;16:19-25.
43.	Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009;87:1246-55.
44.	Böhmig GA, Farkas AM, Eskandary F, Wekerle T. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol 2015;11:732-47.
45.	Zachary AA, Mongomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol Rev 2005;5:373-95.
46.	Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318-26.
47.	Jackson AM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompa-tible kidney transplantation. Kidney Int 2015; 87:409-16.
48.	Mannu GS, Bettencourt-Silva JH, Gilbert J. The ideal timing of ureteric stent removal in transplantation patients. Transpl Int 2014;27: e96-7.
49.	Parapiboon W, Ingsathit A, Disthabanchong S, et al. Impact of early ureteric stent removal and cost-benefit analysis in kidney transplant recipients: Results of a randomized controlled study. Transplant Proc 2012;44:737-9.
50.	Ali Asgari M, Dadkhah F, Tara SA, et al. Early stent removal after kidney transplantation: Is it possible? Nephrourol Mon 2016;8:e30598.
51.	Sutariya V, Tank A. An audit of laparoscopic cholecystectomy in renal transplant patients. Ann Med Health Sci Res 2014;4:48-50. [PUBMED] [Full text]
52.	ADA Clinical Practice Guideline; 2015. Available from: http://www.ada.org/en/member-center/oral-health-topics/antibiotic-prophylaxis. [Last accessed on November 5, 2018].

Correspondence Address:
Ziad Arabi
Division of Adult Transplant Nephrology, Department of Organ Transplant Center, King Abdulaziz Medical City, Riyadh
Saudi Arabia